Literature DB >> 210232

Target antigens for H-2-restricted vesicular stomatitis virus-specific cytotoxic T cells.

R M Zinkernagel, A Althage, J Holland.   

Abstract

Cytotoxic thymus-derived lymphocytes from mice infected with vesicular stomatitis virus (VSV) are H-2 restricted and virus specific for the Indiana and New Jersey strains of VSV. VSV-Indiana-immune T cells can lyse target cells infected with the temperature sensitive (ts) mutant ts 045 about 30 times better when target cell infection occurs at the permissive rather than the non-permissive temperature. Since this mutant fails to express the glycoprotein at the cell surface when grown at the nonpermissive temperature, our results support the view that the viral glycoprotein is involved in defining the major target antigen for VSV-specific T cells. However, the tl 17 mutant that expresses a mutant glycoprotein at the cell surface was lysed, suggesting that the expressed mutated glycoprotein can cross-react with Indiana wild-type glycoprotein. Targets infected at the nonpermissive temperature with VSV ts G31 (mutant in the matrix protein) are still susceptible to T cell-mediated lysis but at a lower level of sensitivity. These results are compatible with the interpretation that for VSV-specific T cell lysis of infected target cells, the viral glycoprotein is a major target antigen and must be expressed, and that the matrix protein plays a lesser role, probably by indirectly influencing glycoprotein configuration at the cell surface.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 210232

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections.

Authors:  Andrea Marzi; Heinz Feldmann; Thomas W Geisbert; Darryl Falzarano
Journal:  J Bioterror Biodef       Date:  2011-09-25

2.  Fewer protective cytotoxic T-cell epitopes than T-helper-cell epitopes on vesicular stomatitis virus.

Authors:  T M Kündig; I Castelmur; M F Bachmann; D Abraham; D Binder; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

3.  Natural killer cell recognition of target cells expressing different antigens of vesicular stomatitis virus.

Authors:  J R Moller; B Rager-Zisman; P C Quan; A Schattner; D Panush; J K Rose; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

4.  N protein is the predominant antigen recognized by vesicular stomatitis virus-specific cytotoxic T cells.

Authors:  L Puddington; M J Bevan; J K Rose; L Lefrançois
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

5.  Generation of cytolytic T lymphocytes after reovirus infection: role of S1 gene.

Authors:  R Finberg; H L Weiner; B N Fields; B Benacerraf; S J Burakoff
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

Review 6.  Natural killer cells in resistance to virus-infected cells.

Authors:  B Rager-Zisman; B R Bloom
Journal:  Springer Semin Immunopathol       Date:  1982

7.  Persistence of vesicular stomatitis virus in cloned interleukin-2-dependent natural killer cell lines.

Authors:  K L Rosenthal; R M Zinkernagel; H Hengartner; P Groscurth; G Dennert; D Takayesu; L Prevec
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

8.  Soluble tumour necrosis factor (TNF)-receptor levels in serum as markers of anti-viral host reactivity.

Authors:  C Bartholdy; A Nansen; O Marker; A R Thomsen
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 9.  Prospects for immunisation against Marburg and Ebola viruses.

Authors:  Thomas W Geisbert; Daniel G Bausch; Heinz Feldmann
Journal:  Rev Med Virol       Date:  2010-11       Impact factor: 6.989

10.  Activation of mouse lymphocytes by vesicular stomatitis virus.

Authors:  G W Goodman-Snitkoff; J J McSharry
Journal:  J Virol       Date:  1980-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.